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 Acute heart failure remains a major challenge for clinicians and healthcare 35 
systems.  The number of annual hospitalizations for acute heart failure is rising due to 36 
the aging of the general population and the increasing prevalence of heart failure.  37 
Heart failure is the leading cause of unplanned hospitalizations for patients older than 38 
65 years in developed countries.
1-4
  These acute events impact the natural history of 39 
heart failure progression, as demonstrated by the dramatic increase in the rate of death 40 
and rehospitalizations after an acute heart failure episode.
5-7
  Similarly, unplanned 41 
visits for worsening symptoms requiring intravenous diuretic treatment are also 42 
associated with poor prognosis, with a greater than 4-fold increase in subsequent 43 
mortality.
8, 9
 44 
 The available treatment options (primarily diuretics or vasodilators in 45 
normo/hypertensive patients) provide symptomatic relief,
1, 10
 but no therapies for 46 
acute heart failure have been shown to improve clinical outcomes in prospective, 47 
randomized trials.  Thus, reducing morbidity and prolonging survival remain major 48 
unmet needs for patients with acute heart failure.
10-12
   49 
 Acute heart failure is an ideal target for development of new therapeutic 50 
interventions given its high frequency and negative impact on clinical outcomes.  51 
However, substantial investments in research and development have not yielded proof 52 
of efficacy and safety for any of the therapies tested.  The contrast between the 53 
advances made in acute heart failure compared to other cardiovascular conditions 54 
(e.g., heart failure with reduced ejection fraction, acute coronary syndrome) is 55 
striking.  This experience calls for critical examination of past trials and application of 56 
lessons learned to guide new directions in the field. 57 
 58 
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Results of Recent Mega-Trials in Acute Heart Failure 59 
 The goal of improving outcomes for patients with acute heart failure has 60 
fostered an emphasis on mega-trials, designed to enrol a sufficiently large number of 61 
patients to detect improvements in survival and/or major outcomes (Table 1).
13-23
  A 62 
comprehensive review of the results of all major trials is beyond the scope of this 63 
manuscript, but two recent trials involving vasodilators are discussed, the results from 64 
which were unexpected.    65 
 The Trial of Ularitide Efficacy and Safety in Acute Heart Failure (TRUE-66 
AHF) was a randomized, double-blind, parallel-group, placebo-controlled trial 67 
evaluating the effects of a 48-hour infusion of ularitide (15 ng/kg/min) on the short- 68 
and long-term clinical course of patients with acute heart failure enrolled within 12 69 
hours from presentation.  The study had two co-primary endpoints: cardiovascular 70 
mortality during long-term follow-up (median 15 months) and the early clinical 71 
course (during first 48 hours) assessed through a composite endpoint including death, 72 
worsening heart failure and symptom relief.
24
  A total of 2,157 patients were enrolled, 73 
and no benefit was observed for ularitide versus placebo in either of the co-primary 74 
endpoints.
23
 75 
 The Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard 76 
Therapy in Acute Heart Failure trial-2 (RELAX-AHF-2) was a randomized, double-77 
blind, placebo controlled study that enrolled 6,545 patients with acute heart failure 78 
(defined as dyspnea at rest or with minimal exertion, pulmonary congestion on chest 79 
radiograph, and BNP ≥500 pg/mL or NT-proBNP ≥2000 pg/mL, treated with 80 
intravenous furosemide ≥40 mg before screening, estimated glomerular filtration rate 81 
30-75 ml/min/1.73 m
2
,
 
 and systolic blood pressure >125 mmHg).  Patients were 82 
randomized 1:1 to serelaxin 30 µg/kg/day or placebo.  No difference between 83 
4 
 
treatment groups was observed in the co-primary endpoints of cardiovascular 84 
mortality at 180 days after enrolment (8.7% serelaxin vs. 8.9% placebo, P=0.39) or 85 
worsening heart failure events during the first 5 days of hospitalization (6.9% 86 
serelaxin vs. 7.7% placebo, P=0.10).
25
   87 
 These results raise pertinent questions regarding why these and other acute 88 
heart failure trials have not identified beneficial treatment effects for the therapies 89 
tested.  It is critical to dissect these trials to understand whether the drugs were truly 90 
ineffective, if characteristics inherent to the acute heart failure population or the 91 
clinical settings where they receive care could have played a role, or if flaws in 92 
clinical trial design or execution may have contributed.  Importantly, these clinical 93 
trial results can influence future research strategies and may ultimately enable 94 
discovery of effective treatment options for patients with acute heart failure.   95 
 96 
Key Lessons Learned from Completed Clinical Trials 97 
 The lack of progress in identifying effective therapies for the treatment of 98 
acute heart failure has been disappointing, but a large body of evidence from 99 
prospective, randomized clinical trials conducted over the past decade is now 100 
available and can provide substantial insight into the clinical characteristics and 101 
outcomes of patients with acute heart failure (Table 1).
13-23
  Heterogeneity across 102 
many aspects relevant to acute heart failure has been proposed as a major factor 103 
influencing clinical trial results to date.     104 
 105 
Heterogeneity in Causes of Rehospitalization or Death 106 
 Rehospitalizations and deaths that occur following an episode of acute heart 107 
failure are attributed to several different causes.  A large proportion may be non-108 
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cardiovascular or, at least, not related with heart failure.
26-29
  In the OPTIMIZE-HF 109 
registry, 42% of patients had at least 1 factor that precipitated the hospitalization for 110 
acute heart failure.
30
  The most common contributors were pneumonia or respiratory 111 
condition (15.3%), acute coronary syndrome or ischemia (14.7%), arrhythmia 112 
(13.5%), and uncontrolled hypertension (10.7%).
30
  Other important factors include 113 
infection, poor nutrition, or deconditioning.
31, 32
  Social support, education of the 114 
patient and her/his relatives, home monitoring, and increasing patients’ adherence to 115 
therapy may therefore have a major impact on decreasing rehospitalizations, even in 116 
the absence of any direct impact on the progression of cardiac dysfunction.
33-38
 117 
 Regarding the mode of death, the European Society of Cardiology Heart 118 
Failure Long-Term Registry reported that cardiovascular causes accounted for the 119 
greatest proportion of deaths (51.7%) among patients with acute heart failure.  A 120 
smaller proportion (13.7%) of deaths were related to non-cardiovascular causes, while 121 
the cause of death was unknown in slightly over a third (34.7%) of patients.
7
  This 122 
heterogeneity in precipitants of rehospitalization and mechanisms of death may 123 
obscure the treatment effect of an intervention if the therapy only influences a single 124 
mode of death or cause of hospitalization.
39
 125 
 126 
Heterogeneity in Acute Heart Failure Pathophysiology and Clinical Phenotypes 127 
 It is accepted that multiple pathophysiologic pathways can lead to acute heart 128 
failure.
40
  Treatment strategies applied to the broad population of patients with acute 129 
heart failure have not yielded improvements in outcome.  This experience suggests 130 
that phenotyping patients hospitalized for acute heart failure and administering 131 
treatments specific for the phenotype may be a more effective approach.
41
  The 132 
optimum criteria for determining phenotype has not been defined.  They may include 133 
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purely clinical variables
40
 or also incorporate more sophisticated strategies (e.g., 134 
bioprofiling, multimarker panels).  135 
 Current treatment algorithms always recommend investigation of potential 136 
specific causes of decompensation.
1, 10, 42
  Possible etiologies of acute heart failure 137 
include acute coronary syndromes, hypertensive emergencies, arrhythmias, or 138 
mechanical factors (e.g., acute valve regurgitation, septal rupture, aortic dissection, 139 
pulmonary embolism).  Specific treatment targeting these underlying causes may 140 
dramatically improve both symptoms and clinical outcomes. 141 
 After evaluation of specific aetiologies, patients are further classified based on 142 
the presence of signs of congestion and/or peripheral hypoperfusion.
1
  In addition, 143 
blood pressure remains the most important clinical variable to consider when making 144 
treatment choices.
1, 10, 43
  Variables, such as duration of heart failure diagnosis,
44
 145 
precipitating factors of the acute decompensation,
30, 45
 and comorbidities
46-48
 also 146 
influence subsequent outcomes.  For example, the specific treatment of iron 147 
deficiency has been associated with improved quality of life and reduced 148 
hospitalizations in clinical trials and meta-analyses.
49
 149 
 Despite the exceptions noted above, clinical criteria may be insufficient to 150 
reflect the underlying predominant pathophysiology.  Moreover, clinical 151 
classifications alone in patients with acute heart failure have failed to differentiate 152 
long-term outcomes.
6, 40
  Use of multiple biomarkers may provide more 153 
comprehensive characterization of pathophysiology,
50-54
 and the role of genomic and 154 
proteomic analyses are under investigation.
55
  A multimarker approach that included 155 
high sensitivity cardiac troponin, N-terminal pro-B-type natriuretic peptide, soluble 156 
ST2, and growth differentiation factor-15 on top of known prognostic markers 157 
provided the best prediction of 180-day cardiovascular mortality in an analysis of data 158 
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from RELAX-AHF.
54
  However, it is important to recognize that while these markers 159 
can indicate patients at high risk of poor outcome, they do not necessarily indicate 160 
that the outcome can be impacted by the treatment under study.  Single or multi-161 
biomarkers can reflect a high-risk population, but in order to achieve better precision 162 
in clinical trials, it is important to match the pathophysiology reflected by the 163 
biomarker with a treatment that can interrupt the underlying pathophysiologic 164 
processes.  Using biomarkers to identify a high-risk population is insufficient if the 165 
biomarker does not also provide information on the likelihood of response or non-166 
response to treatment.  Development of biomarker approaches that identify a 167 
predominant pathophysiology may help promote precision medicine by enabling 168 
therapies to be selected that match the prevailing pathophysiology.  However, this 169 
concept remains a hypothesis that needs to be validated in clinical trials.   170 
 171 
Heterogeneity by Geography 172 
 Geographical differences have influenced the results of clinical trials in acute 173 
heart failure.
7, 56-59
  Heart failure trials have become increasingly global in order to 174 
achieve the requisite number of patients and to compensate for lower enrolment rates 175 
in many Western countries, particularly the United States.  The criteria for hospital 176 
admission, treatment approaches, and discharge practices can vary substantially 177 
among countries.  For example, registry data indicate that vasodilators are less 178 
commonly used in the United States (9%), whereas they are used more frequently in 179 
other parts of the world (Europe 33-41%, Japan 78%).
60
  Geographic disparity in use 180 
of inotropes has also been reported (United States 15%, Europe 22-30%, Japan 181 
19%).
60
  Length of stay in the hospital for patients with acute heart failure is much 182 
shorter in the United States compared to Europe, and it is much longer in Japan.
60
  183 
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These differences in length of hospitalization across geographically diverse study 184 
centres affect post-discharge outcomes, primarily early rehospitalization rates, and it 185 
can confound the interpretation of clinical trial results.
5, 23, 56, 61-63
 186 
 187 
Heterogeneity Among Clinical Investigative Sites  188 
 Site characteristics may also have a major influence on outcomes.  An analysis 189 
from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in 190 
Decompensated Heart Failure) showed that high site enrolment rate was associated 191 
with a greater likelihood of patients completing the study protocol.  High study centre 192 
enrolment was also independently associated with lower risk of 30-day death or 193 
rehospitalization.
64
  Low performing centres with poor protocol adherence or 194 
inadequate clinical trial experience may introduce “noise” and decrease the ability to 195 
detect treatment effects.  In some cases, geographic differences may be explained by 196 
differences in execution of study protocols by investigative sites (e.g., enrolment of 197 
ineligible patients, study drug non-adherence
65
), rather than to intrinsic differences in 198 
patient populations. 199 
 Critical processes have been described to achieve optimal site selection in 200 
acute heart failure trials.
66
  Assessing sites’ interest in the topic, creating a sense of 201 
“ownership” among investigative sites, and providing sites with adequate resources to 202 
hire experienced clinical research staff are among key factors that determine the 203 
success of sites in a clinical trial.
66
 204 
 205 
Strategies for Future Acute Heart Failure Clinical Trials 206 
 The most straightforward explanation for the neutral results of acute heart 207 
failure clinical trials completed to date is simply that the treatments tested were not 208 
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effective.  Taking this view, the trials accomplished their primary aim, which is to 209 
determine whether or not a drug is more effective than placebo on patients’ symptoms 210 
or, preferably, outcomes. 211 
 However, some evidence casts doubt on this reasoning.  First, the mechanism 212 
of action of drugs like serelaxin and ularitide should favourably impact the 213 
pathophysiologic mechanisms of acute heart failure.  Second, all the major 214 
prospective, multicentre randomized trials were preceded by smaller phase 2 trials 215 
that demonstrated beneficial effects of the investigational drugs,
67, 68
 although it is 216 
acknowledged that phase 2 results can be unstable due to the relatively small number 217 
of patients or events usually reflected in phase 2 trials.  Specifically, serelaxin 218 
improved multiple endpoints in a first phase IIb trial, pre-RELAX,
68
 and reduced 219 
worsening heart failure and cardiovascular and all-cause mortality in the RELAX-220 
AHF trial.
21
E 221 
 Thus, it is plausible that therapies for acute heart failure that have “failed” in 222 
randomized, controlled trials actually have beneficial effects that remained 223 
undetected.  A variety of factors could contribute to this inability to identify a 224 
treatment effect (if one exists), including suboptimal matching of study drug to patient 225 
phenotype or selecting the wrong timepoint to assess study endpoints.  Addressing 226 
these considerations in future trials, along with the previously mentioned 227 
heterogeneity among patients with acute heart failure, may help generate future 228 
successes.   229 
 230 
Matching Drugs to Pathophysiology  231 
 Investigators in acute heart failure have drawn parallels between acute heart 232 
failure and acute coronary syndromes, since in both cases an acute event is followed 233 
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by an increase in mortality.  In acute coronary syndromes, drugs acting on the primary 234 
pathophysiology (i.e., thrombus formation) improve long-term outcomes.  In acute 235 
heart failure, it was hypothesized that a drug administered in the acute setting could 236 
also exert long-term effects on outcome.  Unfortunately, the critical difference 237 
between acute coronary syndrome and acute heart failure is that acute heart failure 238 
can originate from many different pathophysiologic processes.  The equivalent of a 239 
“clot” for acute heart failure has not yet been identified.  The targeted 240 
pathophysiology model has also worked well for patients with chronic heart failure 241 
and reduced ejection fraction, where mechanisms responsible for disease progression 242 
such as neurohormonal activation, tachycardia, or dyssynchrony are identified and 243 
treated with neurohormonal antagonists, ivabradine, or cardiac resynchronization.
1, 42
   244 
 Better patient phenotyping has also been proposed as a solution to increase the 245 
likelihood of a successful trial.  This approach assumes that patient phenotype might 246 
correlate with the relevant pathophysiology (e.g., matching drugs with renal 247 
protective effects to patients with worsening renal function, vasodilators in patients 248 
with normal to high blood pressure).  Although a logical idea, these trials have also 249 
failed to identify a clinical benefit of treatment.
17-19, 23, 69
  Thus, current clinical and 250 
laboratory based approaches to phenotyping patients with acute heart failure is not 251 
effective to select and target treatment.  Better pathophysiological characterization of 252 
patients with acute heart failure is urgently needed. 253 
 254 
Timing of Endpoint Assessment 255 
 Long-Term Endpoints.  Clinical trial endpoints have been extensively 256 
discussed elsewhere.
70, 71
  A major hallmark of acute heart failure is its high mortality 257 
and readmission rates. Correspondingly, morbidity and mortality endpoints have been 258 
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predominantly used in clinical trials.  However, these endpoints can be problematic in 259 
acute heart failure trials. First, in order to achieve the number of events needed for 260 
adequate statistical power, a large number of patients (i.e., many thousands) must be 261 
enrolled and long-term follow-up is needed, at least 6 months.
25
  The potential 262 
limitations and challenges previously discussed (e.g., inappropriate inclusion of 263 
ineligible patients, geographic differences, poor clinical site performance) are 264 
magnified in large trials.  Second, consistent with the recognition that a single 265 
pathophysiologic process does not fully explain heart failure progression in the setting 266 
of an acute event, it seems unlikely that short-term (e.g., 48 hours) administration of a 267 
drug would have long-term effects on outcomes.   268 
 The most effective therapy for acute episodes of decompensation seems to be 269 
prevention.  Treatments effective in chronic heart failure have also reduced heart 270 
failure related hospitalizations.
1, 42
  It remains, however, to be shown whether the 271 
initiation of an appropriate treatment at the time of discharge, or shortly thereafter, 272 
and its continuation post-discharge may have beneficial effects on long-term 273 
outcomes.  Observational data suggest that beta-blocker use at the time of hospital 274 
discharge is associated with better survival 60-90 days post-discharge.
72
  A propensity 275 
matched analysis of 19,980 patients with acute heart failure enrolled in the GREAT 276 
network registry showed that patients receiving a beta blocker at discharge had a 277 
lower 90-day mortality (HR 0.56, 95% CI 0.46-0.69) and 1-year mortality (HR 0.62, 278 
95% CI 0.55-0.71) than untreated patients.
73
  Similar findings were reported for 90-279 
day (HR 0.53, 95% CI 0.42-0.66) and 1-year mortality (HR 0.62, 95% CI 0.53-0.72) 280 
in patients discharged on a renin angiotensin system inhibitor compared to those not 281 
treated.
73
  These findings, while observational, are strengthened by the knowledge that 282 
these drug classes have been shown to prolong survival and reduce hospitalizations in 283 
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prospective, randomized trials in patients with chronic heart failure with reduced 284 
ejection fraction.  Thus, optimizing the use of chronic, guideline recommended 285 
evidence based therapies before discharge in patients hospitalized for acute heart 286 
failure should be a priority. 287 
 Short-term endpoints.  Short-term endpoints may be less ambitious but are 288 
potentially more likely to succeed.  However, which endpoints are most suitable is a 289 
topic of debate.  Biomarkers, specifically natriuretic peptides, are associated with 290 
patients’ outcomes and have often been used as surrogates for outcomes.  However, 291 
the relationship between the effect of drug therapy on natriuretic peptides and 292 
outcomes have been inconsistent across trials.
14, 15, 74, 75
  293 
 Short-term clinical endpoints may be more attractive.  Worsening heart failure 294 
is defined as worsening symptoms requiring reinitiation or increasing doses of 295 
intravenous treatment or mechanical devices during the hospitalization for heart 296 
failure.  It occurs in 4 to 37% of patients hospitalized for heart failure, and it is 297 
associated with higher plasma levels of natriuretic peptides and troponin, worsening 298 
renal function, longer length of the hospital stay, increased post-discharge 299 
hospitalizations, deaths, and higher healthcare costs post-discharge.
76-78
  Worsening 300 
heart failure is also sensitive to drug treatment.
15, 21, 76, 79
  However, it is also highly 301 
dependent on the investigator or patient reporting events, as well as the specific 302 
definition used to identify worsening heart failure events.
79
  The occurrence of 303 
worsening heart failure events has declined in recent trials, possibly due to the 304 
increased complexity of case report forms and resultant underreporting.  305 
 Length of stay for the initial hospitalization for acute heart failure may also be 306 
reduced with appropriate treatment.
21, 68
  It is clinically relevant and significantly 307 
impacts on the costs of healthcare.  However, it also has marked geographical 308 
13 
 
differences and is strongly influenced by local treatment patterns.  Evaluating 309 
proportional rather than absolute length of stay may be one approach to overcome the 310 
limitations of regional/cultural differences in length of stay.  Symptom relief is 311 
clinically meaningful, but its subjectivity results in substantial variability in large 312 
multicentre trials.  Furthermore, current treatment (e.g., intravenous diuretics) is 313 
generally effective for symptomatic relief in most patients.  Because of this treatment 314 
response, demonstrating additional treatment effects on symptoms for a new therapy 315 
is difficult.  Additionally, a new therapy may not be considered valuable to health 316 
systems and payers if the symptomatic improvement is the same or only marginally 317 
greater than inexpensive standard therapy (i.e., diuretics) without some evidence of 318 
other clinical benefit.  Signs of congestion are related with outcomes, and they may 319 
persist at the time of discharge.
80, 81
  Thus, better congestion relief may be a 320 
meaningful endpoint, but accurate assessment tools and validation studies are lacking.  321 
 322 
Conclusions 323 
 Acute heart failure remains a major challenge for clinical practice.  Current 324 
treatment is insufficient as patients continue to have poor outcomes.  Short-term 325 
treatment is unlikely to affect long-term mortality and/or rehospitalization rates.  326 
Thus, composite endpoints based on symptom relief and short-term events may be 327 
better suited to gauge the effects of drug treatment.  Long-term outcomes are more 328 
likely to be improved by adherence to evidence-based therapies for chronic heart 329 
failure to prevent new episodes of decompensation. 330 
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 Table 1.  Overview of Major Randomized, Controlled Trials with new drugs in Acute Heart Failure
13-23
 808 
 809 
Trial 
Study drug vs. 
comparator 
Patient 
Population 
Primary Endpoint Duration 
of 
Treatment 
Primary Results 
(Study Drug vs. Control) 
Potential 
Contributors to 
Results 
OPTIME
13
 
Milrinone vs. placebo 
(on top of standard care) 
N=949, ADHF, 
<48 hours since 
admission, LVEF 
<40% 
Number of days 
hospitalized for CV 
causes or dead 
within 60 days after 
randomization 
48 hours Median 6 days vs. 7 days, P=0.71 Mismatch of 
patient population 
to drug mechanism 
of action (patients 
congested, not low 
output) 
SURVIVE
14
 
Levosemindan vs. 
dobutamine 
N=1,327, ADHF, 
need inotropic 
support, LVEF 
<30%, SBP ≥85 
mmHg 
180-day all-cause 
mortality 
24 hours 
(min) 
26% vs. 28%, HR 0.91, 95% CI 0.74-
1.13, P=0.4 
Active controlled 
study 
REVIVE
15
 
Levosemindan vs. 
placebo (on top of 
standard care) 
 
N=600, ADHF, 
dypneic at rest 
despite IV 
diuretic 
treatment, LVEF 
≤35%, SBP ≥90 
mmHg 
Clinical 
classification of 
improved, 
unchanged, or 
worse during first 5 
days 
24 hours Improved:  58 vs. 44 
Worse:  58 vs. 82 
P=0.015 for between-group difference 
HR for 90-day all-cause mortality:  
1.33, 95% CI 0.85-2.06 
Hypotension 
EVEREST
16
 
Tolvaptan vs. placebo 
(on top of standard care) 
N=4,133, ADHF, 
volume overload, 
NYHA class 
III/IV, <48 hours 
since admission, 
LVEF ≤40% 
Co-primary:  all-
cause mortality; 
composite of CV 
death or 
hospitalization for 
HF (median follow-
60 days All-cause mortality:  25.9% vs. 26.3%, 
HR 0.98, 95% CI 0.87-1.11, P=0.68 
(superiority) 
 
CV death or HF hospitalization:  42% 
vs. 40.2%, HR 1.04, 95% CI 0.95-1.14, 
Mismatch of 
patient population 
to drug mechanism 
of action (i.e., 
patients may not 
have had elevated 
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Trial 
Study drug vs. 
comparator 
Patient 
Population 
Primary Endpoint Duration 
of 
Treatment 
Primary Results 
(Study Drug vs. Control) 
Potential 
Contributors to 
Results 
up 9.9 months)  P=0.55 vasopressin levels, 
only 8% had 
hyponatremia) 
VERITAS program
17
 
Tezosentan vs. placebo 
(on top of standard care) 
N=1,448, ADHF, 
persistent 
dyspnea at rest, 
<24 hours since 
admission, SBP 
≥100 mmHg (or 
≥120 mmHg if 
concomitant 
vasodilator) 
Individual studies:  
Change from 
baseline in dyspnea 
over first 24 hours 
 
Combined studies:  
incidence of death 
or worsening HF at 
7 days 
24-72 
hours 
Dyspnea:  no difference in area under 
the curve for change in dyspnea from 
baseline 
 
Death or worsening HF at day 7:  
26.3% vs. 26.4%, P=0.95 
Challenges 
associated with 
dyspnea 
assessment (e.g., 
rapid response of 
dyspnea to standard 
therapy, knowledge 
of hemodynamics, 
uncertain 
sensitivity of 
dyspnea 
assessment 
instruments); 
adverse effects 
(hypotension) 
PROTECT
18
 
Rolofylline vs. placebo 
(on top of standard care) 
N=2,033, ADHF, 
persistent 
dyspnea at rest or 
minimal activity, 
estimated CrCl 
20-80 ml/min, 
<24 hours since 
admission, SBP 
Treatment success, 
failure or no 
change in clinical 
condition 
Up to 3 
days 
No difference in distribution of 
primary composite endpoint; more 
patients in rolofylline group met 
critieria for treatment success (OR 
1.22, 95% CI 1.01-1.47, P=0.04) but 
also for treatment failure (OR 1.13, 
95% CI 0.90-1.42, P=0.30); numerical 
excess of rolofylline treated patients 
Inadequate 
understanding of 
contribution of 
cardiorenal 
syndrome to ADHF 
pathophysiology 
(i.e., role of 
psuedoworsening 
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Trial 
Study drug vs. 
comparator 
Patient 
Population 
Primary Endpoint Duration 
of 
Treatment 
Primary Results 
(Study Drug vs. Control) 
Potential 
Contributors to 
Results 
≥95 mmHg who met criteria for worsening renal 
function (12.7% vs. 11.1%, P=0.31) 
renal function in 
setting of ADHF) 
ASCEND-HF
19
 
Nesiritide vs. placebo 
(on top of standard care) 
 
N=7,141, ADHF, 
dyspnea at rest 
with minimal 
activity, <24 
hours after first 
intravenous 
treatment for 
ADHF, SBP ≥100 
mmHg (or ≥110 
if concomitant 
intravenous 
nitroglycerin) 
Co-primary:  
Change in self-
reported dyspnea at 
6 and 24 hours; 
composite of all-
cause mortality or 
HF hospitalization 
at 30 days 
24 hours to 
7 days 
Moderate or marked improvement in 
dyspnea at 6 hours:  44.5% vs. 42.1% 
(P=0.03, did not meet pre-specified 
criteria for significance) 
Moderate or marked improvement in 
dyspnea at 24 hours:  68.2% vs. 66.1% 
(P=0.007, did not meet pre-specified 
criteria for significance) 
All-cause mortality or HF 
hospitalization at 30 days:  9.4% vs. 
10.1% (HR 0.93, 95% CI 0.8-1.08) 
Coadministratio of 
other therapies that 
relieve congestion; 
limitations of 
dyspnea 
assessment 
instruments (i.e., 
minimal clinically 
important 
differences); lower 
than expected event 
rate 
ASTRONAUT
20
 
Aliskiren vs. placebo 
(on top of standard care) 
N=1,639, ADHF 
after 
hemodynamic 
stabilization, 
history of chronic 
HF, LVEF ≤40% 
First occurrence of 
CV death or HF 
rehospitalization at 
6 months 
12 months 24.9% vs. 26.5%, HR 0.92, 95% CI 
0.76-1.12, P=0.41 
Limited potential 
for beneficial 
treatment effect of 
additional RAAS 
blockade; influence 
of comorbidities 
(i.e., diabetes 
mellitus); influence 
of adverse effects 
(e.g., 
hyperkalemia, renal 
impairment, 
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Trial 
Study drug vs. 
comparator 
Patient 
Population 
Primary Endpoint Duration 
of 
Treatment 
Primary Results 
(Study Drug vs. Control) 
Potential 
Contributors to 
Results 
hypotension) 
RELAX-AHF
21
 
Serelaxin vs. placebo 
(on top of standard care) 
N=1,161, ADHF, 
presented within 
16 hours, treated 
with ≥40 mg 
intravenous 
furosemide before 
screening, SBP 
>125 mmHg 
Co-primary:  
Change in patient-
reported dyspnea 
quantified by area 
under curve of 
visual analogue 
scale scores 
through day 5; 
moderately or 
markedly improved 
patient reported 
dyspnea using 7-
point Likert scale at 
6, 12, and 24 hrs 
(responders were 
those with 
moderate or 
marked 
improvement at all 
timepoints) 
Up to 48 
hours 
Area under curve of visual analogue 
scale:  Greater change from baseline 
for serelaxin (2756 mm x hr vs. 2308 
mm x hr, P=0.007) 
 
Likert scale marked or moderate 
improvement:  35.8% vs. 31.4% at 6 
hrs (P=0.113), 50.3% vs. 44.6% at 12 
hrs (P=0.051), 67.9% vs. 63.1% at 24 
hrs (P=0.086) 
 
Secondary efficacy (days alive and out 
of hospital to day 60):  48.3 days vs. 
47.7 days, P=0.37 
 
CV death or hospitalization for HF or 
renal failure to day 60:  13.2% vs. 
13%, HR 1.02, 95% CI 0.74-1.41, 
P=0.89 
 
CV death:  6.1% vs. 9.6%, HR 0.63, 
95% CI 0.41-0.96, P=0.028 
Lower risk 
population (based 
on placebo group 
30-day all-cause 
mortality of 3%, 
lower than 
VERITAS and 
ASCEND); 
limitations of 
dyspnea 
assessment 
instruments (i.e., 
minimal clinically 
important 
differences); 
RELAX-AHF-2
22
 
Serelaxin vs. placebo 
(on top of standard care) 
N=6,545, ADHF, 
randomized 
within 16 hours, 
Co-primary:  CV 
mortality at 180 
days; worsening 
48 hours No difference in CV mortality at 180 
days between groups 
 
Short-term drug 
administration 
unlikely to impact 
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Trial 
Study drug vs. 
comparator 
Patient 
Population 
Primary Endpoint Duration 
of 
Treatment 
Primary Results 
(Study Drug vs. Control) 
Potential 
Contributors to 
Results 
SBP ≥125 mmHg HF through day 5 Non-significant trend towards 
reduction in worsening HF through day 
5 
long-term 
outcomes; small 
number of deaths 
in RELAX-AHF 
may explain 
discrepancy in 
findings between 
two studies 
TRUE-HF
23
 
Ularitide vs. placebo (on 
top of standard care) 
N=2,157, ADHF 
(ER or 
hospitalization), 
study drug 
initiation within 
12 hours, 
persistent 
dyspnea 2 hours 
after ≥40 mg 
intravenous 
furosemide, SBP 
116-180 mmHg 
Co-primary:  CV 
death (median 
follow-up 15 
months); 
hierarchical clinical 
composite during 
first 48 hours 
48 hours CV death:  21.7% vs. 21%, HR 1.03, 
96% CI 0.85-1.25, P=0.75 
 
Hierarchical composite:  Improved 
48.6% vs. 47.5%; unchanged 44.8% vs. 
44.2%; worse 6.6% vs. 8.3%, P=0.82 
for distribution 
Despite evidence of 
hemodynamic 
improvement and 
reduction in wall 
stress, no benefit 
on long-term 
outcomes 
suggesting that 
rapid cardiac 
decongestion does 
not influence that 
natural history of 
heart failure 
progression  
CV, cardiovascular; ADHF, hospitalized for acute decompensated heart failure; CrCl, creatinine clearance; ER, emergency room; LVEF, left 810 
ventricular ejection fraction; RAAS, renin angiotensin aldosterone system; SBP, systolic blood pressure 811 
 812 
